Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Contract revenue	$ 0	$ 2,717
Operating expenses
Research and development	36,607	26,482
General and administrative	26,844	27,834
Total operating expenses	63,451	54,316
Loss from operations	(63,451)	(51,599)
Other income (expense), net
Interest income and other, net	1,248	89
Loss on extinguishment of debt	0	(700)
Interest expense and other, net	(1,071)	(466)
Change in estimated fair value of preferred unit warrant	0	(371)
Loss before income taxes	(63,274)	(53,047)
Income tax expense (benefit)	(70)	(41)
Net loss	(63,344)	(53,088)
Net loss attributable to non-controlling interest	(32,756)	(44,757)
Net loss attributable to Rani Therapeutics Holdings, Inc.	$ (30,588)	$ (8,331)
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-basic	$ (1.28)	$ (0.43)
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-diluted	$ (1.28)	$ (0.43)
Weighted average Class A common share outstanding-basic	23,817	19,534
Weighted average Class A common share outstanding-diluted	23,817	19,534
Common Class A [Member]
Other income (expense), net
Net loss attributable to Rani Therapeutics Holdings, Inc.	$ (30,588)	$ (8,331)
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-basic	$ (1.28)	$ (0.43)
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-diluted	$ (1.28)	$ (0.43)
Weighted average Class A common share outstanding-basic	23,817	19,534
Weighted average Class A common share outstanding-diluted	23,817	19,534